For instance, blinatumomab, a bispecific antibody binding CD19 and CD3, and CD19-directed chimeric antigen receptor (CAR) T-cells, have been approved for clinical use in both adults and children with B-cell precursor ALL [13,14,15]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.